Specification of Analysis

Femara is an oral non-steroidal inhibitor for the treatment of hormonally-responsive breast cancer after surgery.  Femara  prevents the aromatase from producing estrogens by competitive, reversible binding to the heme of its cytochrome p450 unit, the action is specific,and Femara does not reduce production of mineralo-or corticosteroids.Femara is a new generation aromatase inhibitor, is a synthetic derivative of benzyl triazole, Femara by inhibiting aromatase, estrogen levels drop, thereby eliminating the stimulating effect of estrogen on tumor growth. Chemotherapy and radiotherapy for breast cancer.

Function

1. Treatment of postmenopausal women with advanced breast cancer (estrogen receptor, progesterone receptor positive
or unknown receptor status), used for anti-estrogen therapy after the failure of second-line treatment;
2. For locally advanced or spread after the first-line treatment of postmenopausal breast cancer (foreign data);
3. For the received standard adjuvant therapy in postmenopausal breast cancer after five years of adjuvant
therapy in patients with extension (foreign data);
4. Postoperative adjuvant therapy for hormone-positive early breast cancer patients.